issued
on 06 Feb 2024
Last Applicant/ Owned by
60 Leveroni Court
Novato
CA
94949
Serial Number
97726798 filed on 21st Dec 2022
Registration Number
N/A
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
Pharmaceutical, scientific, and medical research and development in the field of gene therapy manufacturing technology; biomedical and scientific research in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic diseases, gene therapy, and cell therapy; biomedical research in the field of gene therapy design and delivery; gene therapy design and delivery developm Read More
Licensing of intellectual property; online social networking services in the field of rare diseases and disorders
providing medical services, namely, gene therapy design and delivery services being gene therapy medical services in the field of liver, hepatological, cardiovascular, central nervous system, endocrine, inflammatory, metabolic, autoimmune, musculoskeletal, neurological, ophthalmologic, respiratory, and hematologic diseases and disorders; medical consulting services in the field of rare diseases and disorders; healthcare services, namely, providing an online database of medical and healthcare information in the field of rare diseases and disorders, and collecting data and information on rare diseases and disorders for screening, diagnosis and treatment purposes; medical information services in the nature of providing a database in the field of hypophosphatemia information based on collected patient data and information all for treatment and diagnostic purposes
Pharmaceutical, scientific, and medical research and development in the field of gene therapy manufacturing technology; biomedical and scientific research in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic diseases, gene therapy, and cell therapy; biomedical research in the field of gene therapy design and delivery; gene therapy design and delivery development of biochemical assays; product development in the fields of genetic therapies and effectors to regulate, modulate, and characterize disease states; pharmaceutical research and development in the field of gene therapy; scientific research in the nature of conducting clinical trials for others in the field of gene therapy design and delivery; scientific and medical research, namely, compiling and sharing of patient data for research purposes in the field of rare diseases and disorders; medical and scientific research information in the field of rare diseases and disorders; computer services, namely, creating an on-line community for registered users to obtain feedback from their peers, interact with research data, and share data in the field of rare diseases and disorders; pharmaceutical research services, namely, recruitment of rare disease patients for panels such as pharmaceutical research panels; providing medical research and scientific research information in the field of hypophosphatemia
education and training services, namely, seminars, providing non-downloadable webinars, and workshops for healthcare professionals, caregivers, patients, and providers in the field of rare diseases and disorders; online journals, namely, blogs featuring information on rare diseases and disorders
financial and insurance consultation services, namely, patient advisory, support and consultancy services regarding patient finances, insurance and access to medical treatment; providing financial and insurance information, namely, providing information and guidance in connection with health insurance benefit plans and other patient financial assistance resources; financial and insurance consultation services, namely, insurance and medical and pharmaceutical access consultation services, namely, assisting patients and their caregivers to identify the scope of coverage offered by patient medical and pharmaceutical insurance and to identify other financial assistance resources for payment of patient treatment; insurance consultation services, namely, assisting patients and their caregivers to obtain authorization and payment for medical and pharmaceutical costs
printed publications, namely, books, brochures, informational pamphlets, informational cards, and advertisements being signs and boards of paper in the field of rare diseases and disorders
downloadable software for creating, editing, uploading, downloading, accessing, viewing, posting, displaying, tagging, blogging, streaming, linking, annotating, indicating sentiment about, commenting on, embedding, transmitting, and providing electronic media information via computer, the internet and communication networks in the field of rare diseases and disorders; downloadable software for modifying and enabling transmission of images, audio, audio visual and video content and data in the field of rare diseases and disorders; downloadable computer software for use in inputting, gathering, monitoring, sharing, and analyzing patient data with respect to medical histories, health status and disease progression and treatment
Pharmaceutical preparations for the treatment of liver, hepatological, cardiovascular, central nervous system, inflammatory, autoimmune, musculoskeletal, ophthalmologic, respiratory, osteopathic, oncologic, endocrine, orthopedic, metabolic, lipid-related, genetic, neuromuscular, autosomal, lysosomal storage, enzyme, hematologic and long-chain fatty acid oxidation disorders (LC-FAOD) diseases and disorders; chemical, biological, and biochemical preparations for use in gene delivery technology for medical use, namely, nucleic acids, including coding and non-coding deoxyribonucleic acids, plasmids, vectors, promotors, enhancers and other regulatory sequences, for use in in vivo therapeutic use in gene therapy
Chemical, biological, and biochemical preparations for use in gene delivery technology, namely, nucleic acids, including, coding and non-coding deoxyribonucleic acids, plasmids, vectors, promotors, enhancers and other regulatory sequences, for use in vitro laboratory use; chemical, biological, and biochemical preparations for use in the manufacture of pharmaceutical preparations
No 97726798
No Service Mark
No 315613-20000
No
No
No
No
No
No
No
No
The mark consists of the word "ultragenyx" in a lower-case stylized font.
Status Date | Action Taken |
---|---|
06th Feb 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
12th Dec 2023 | PUBLISHED FOR OPPOSITION |
12th Dec 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
22nd Nov 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
06th Nov 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
03rd Nov 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
03rd Nov 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
03rd Nov 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
25th Sep 2023 | NON-FINAL ACTION WRITTEN |
25th Sep 2023 | NON-FINAL ACTION E-MAILED |